-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications?
Review
(4011) Views (797) Full article downloads
Authors: Lina Nordquist, M Johansson
Published Date September 2008
Volume 2008:4(6) Pages 1283 - 1288
DOI: http://dx.doi.org/10.2147/VHRM.S3955
Lina Nordquist1, M Johansson2
1Department of Medical Cell Biology, Division of Integrative Physiology, Uppsala University, Uppsala, Sweden; 2Department of Pathology, University of California, San Francisco, San Francisco, USA
Abstract: The proinsulin connecting peptide, C-peptide, is a cleavage product of insulin synthesis that is co-secreted with insulin by pancreatic β-cells following glucose stimulation. Recombinant insulin, used in the treatment of diabetes, lacks C-peptide and preclinical and clinical studies suggest that lack of C-peptide may exacerbate diabetes-associated complications. In accordance with this, several studies suggest that C-peptide has beneficial effects in a number of diabetes-associated complications. C-peptide has been shown to prevent diabetic neuropathy by improving endoneural blood flow, preventing neuronal apoptosis and by preventing axonal swelling. In the vascular system, C-peptide has been shown to prevent vascular dysfunction in diabetic rats, and to possess anti-proliferative effects on vascular smooth muscle cells, which may prevent atherosclerosis. However, C-peptide depositions have been found in arteriosclerotic lesions of patients with hyperinsulinemic diabetes and C-peptide has been shown to induce pro-inflammatory mediators, such as nuclear factor kappa B, inducible nitric oxide synthase, and cyclooxygenase-2, indicating that C-peptide treatment could be associated with side-effects that may accelerate the development of diabetes-associated complications. This review provides a brief summary of recent research in the field and discusses potential beneficial and detrimental effects of C-peptide supplementation.
Keywords: C-peptide, proinsulin, diabetes, cardiovascular
Other articles by Dr Lina Nordquist
Readers of this article also read:
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Corrigendum
Erratum
Erratum
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Primary care for diabetes mellitus: perspective from older patients
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




